RxDoctor Payments DataLook up a doctor →

Kevin Balter, MD

Interventional Pain Medicine · Omaha, NENPI 1568472520

Payments from drug & device makers

$11,333in general payments, 2019–2025

Across 427 payments — averaging $26.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zavation Medical Products, LLC$2K
  • AbbVie$1K
  • Genesys Orthopedics Systems, L.L.C.$1K
  • Stimwave Technologies Incorporated$927
  • Medtronic$797
  • Abbott$705
  • plus $5K from 48 others

What the payments were for

  • Travel & lodging$3,47431%
  • Food & beverage$7,84369%
  • Gifts$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional pain medicine providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$63,732
Medicare patients
121
Services billed
916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl57$48,494
Buprenorphine117$27,482
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen33$27,101
BotoxOnabotulinumtoxina17$26,889
Xtampza ErOxycodone Myristate48$26,524
Fentanyl30$3,110
Lidocaine21$3,003
Diclofenac Sodium20$2,208
Morphine Sulfate ErMorphine Sulfate77$2,080
Buprenorphine Hcl105$1,739
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen47$1,161
Pregabalin63$997
Gabapentin66$951
Tramadol Hcl44$588
Methocarbamol17$400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$1,286$26,88917 claims
Collegium Pharmaceutical, Inc.Xtampza Er$310$26,52448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional pain medicine providers in Nebraskaon file to place this against a meaningful peer group, so we don't.

Other interventional pain medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →